Life Science Intelligence

  Moderator Christian Espinosa from Blue Goat Cyber discuss how weak cybersecurity measures can critically delay or prevent medtech companies from successfully entering the market. For more information watch this video: https://www.youtube.com/watch?v=5Uc1lSvDNBk

Join moderator Etienne Nichols from Greenlight Guru and expert Jon Norris from HSBC Innovation as they discuss current trends, challenges, and growth opportunities shaping the medtech and venture capital markets today. For more information watch this video: https://www.youtube.com/watch?v=yti5J6RcKXo

As a visionary biomedical informatician, pediatrician, and biotech entrepreneur, Dr. Atul Butte leaves behind an extraordinary legacy, defined not only by his groundbreaking work in data-driven medicine, but also by his contagious positivity and unwavering commitment to uplifting others. He was as fierce an advocate for human potential as he was for scientific progress, and the fields of translational and clinical bioinformatics that he pioneered will benefit for generations to come. Here, we pay tribute to his transformative work and passion for human health. “Once we let data flow,lifelong discoveries become possible.” This statement truly defines the transformational achievements and life of  Atul Butte, MD, PhD , a respected champion in the use of big data in science and health, and one of the most highly cited researchers in his field. When he walked on stage at a recent LSI USA event in Dana Point, CA to give a compelling keynote address, entitled “Precisely Practicing Medici...

Olympus Corporation and Revival Healthcare Capital made headlines this week by formalizing a build-to-buy agreement. Under the terms, Olympus gains exclusive rights to acquire Swan EndoSurgical, a company it co-incubated with Revival to develop a next-generation robotic platform for endoluminal surgery. The potential price tag? Up to $458 million, starting with a $65 million initial investment from Olympus. The deal positions Olympus to expand into high-value gastrointestinal (GI) interventions while reducing the risk typically associated with acquiring early-stage technologies. Why Build-to-Buy Deals Are Gaining Momentum Build-to-buy partnerships, also known as structured deals or option-to-acquire models, have been part of medtech for years, but they are now emerging as a preferred approach for capital-efficient innovation. In these arrangements, a strategic partner invests in a startup early, offering not just financial backing but also clinical, regulatory, and commercial expertise...

Calla Lily Clinical Care is challenging outdated norms in women’s health with Callavid, a first-of-its-kind vaginal drug delivery platform designed to replace painful daily injections and leaky pessaries. Co-founded by pediatric emergency physician-turned-entrepreneur Dr. Lara Zibners and private equity investor and medtech entrepreneur Thang Vo-Ta, the company is addressing the often-overlooked shortcomings of fertility and gynecologic care. A Physician’s Mission to Fix What She Endured Dr. Lara Zibners didn’t set out to become a startup founder. As a board-certified pediatric emergency medicine specialist and trauma educator, she spent her career treating patients, not pitching to investors. But seven failed IVF rounds and the physical and emotional toll of progesterone treatment changed everything. “It was, by far, other than not getting pregnant, the most traumatic part of IVF,” Zibners said. Her transition to entrepreneurship began when she was advising a company with a leak-free ...

 Under the direction of CEO Eyal Ben Esti, MicroSteer is pioneering an add-on device that transforms how physicians remove complex colorectal lesions. By decoupling dissection control from the endoscope, the company’s robotic, single-use system aims to make advanced therapeutic endoscopy safer, faster, and accessible to far more physicians. Based in Israel and leveraging the country’s medtech innovation ecosystem, MicroSteer is initially targeting the U.S. market before expanding into Europe and Asia. Origin Story MicroSteer was founded to address a critical bottleneck in the treatment of colorectal lesions, a leading cause of cancer-related deaths worldwide. “The current standard for removing large or flat GI polyps is prone to high complication rates, requires significant specialist expertise, and frequently results in costly surgical referrals,” said Ben Esti. Co-founders Adi Strauss (CTO) and Ofer Pillar (CBO) envisioned a solution that blends innovative mechanics, robotic...

  As we enter the second half of 2025, the medtech industry continues to showcase its resilience despite external challenges. Quarterly earnings season is a key opportunity to evaluate how major players in the industry are faring amid global economic uncertainty, geopolitical tensions, and shifting healthcare policies. Here, we review the financial performance of some of the largest players in the medtech sector in Q2 2025, providing insights into the trends shaping the market and what these results mean for the industry’s outlook. Q2 2025 Medtech Earnings: Performance Highlights The latest data from Q2 earnings reports reveal a mix of growth, strategic adjustments, and a few challenges for medtech companies. While some companies continue to thrive, others are adjusting their strategies to stay competitive in a changing landscape. Let’s break down the numbers and trends. Abbott: Leading with Strong Growth Abbott’s Q2 revenue for its medtech business reached $18.9 billion, reflectin...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, enter strategic partnerships, receive FDA Breakthrough Device designation, and much more on the road to  LSI Europe  ’25 in London (September 7–11). BMI OrganBank Secured FDA Breakthrough Device designation for its novel room temperature machine perfusion (RTMP) platform for kidney preservation. The designation supports upcoming clinical studies and highlights the potential to improve transplant outcomes and reduce waitlist times. Cern Formed a strategic partnership with Elmstead Partners, bringing capital and life sciences expertise to support Cern’s women’s health innovation. The company’s microbicidal light-based device for treating both yeast and bacterial vaginosis is now in human clinical trials in the U.S. CorNeat Vision Appointed Tzvika (Mike) Fisher as Chief Operations Officer to support operational scaling and global growth. His experience in str...